Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.
2019
AO Cuneo
Tipo pubblicazione
Research Support, Non-U.S. Gov't
Autori/Collaboratori (27)Vedi tutti...
Marmorino F
Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.
Rossini D
Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.
Lonardi S
Department of Clinical and Experimental Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padova.
et alii...
Abstract
BACKGROUND: The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 years with ECOG PS ?2 and between 71 and 75 years with ECOG PS?=?0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender. PATIENTS AND METHODS: Subgroup analyses according to age (<70 versus 70-75?years) and gender were carried out for overall response rate (ORR), progression-free survival (PFS), and AE rates. RESULTS: Of 1187 patients, 1005 (85%) were aged <70?years and 182 (15%) 70-75?years; 693 (58%) were males and 494 (42%) females. There was no evidence of interaction between age or gender and the benefit provided by the intensification of the upfront chemotherapy in terms of ORR and PFS, or the increased risk of experiencing G3/4 AEs. Elderly patients and females experienced higher rates of overall G3/4 AEs (73% versus 60%, P?
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 31573612
DOI : 10.1093/annonc/mdz403
Keywords
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects; Age Factors; Aged; Aged, 80 and over; metastatic colorectal cancer; gender; Vomiting/chemically induced/pathology; Treatment Outcome; Sex Characteristics; Progression-Free Survival; Organoplatinum Compounds/administration & dosage/adverse effects; Neoplasm Metastasis; Leucovorin/administration & dosage/adverse effects; Kaplan-Meier Estimate; Humans; Fluorouracil/administration & dosage/adverse effects; Female; Colorectal Neoplasms/drug therapy/epidemiology/pathology; Camptothecin/administration & dosage/adverse effects/analogs & derivatives; age; FOLFOXIRI/bevacizumab; Nausea/chemically induced/pathology; Male; Middle Aged; Bevacizumab/administration & dosage/adverse effects;